Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCOHKU)

Drug Name

PMID21967808CR-16 Drug Info

Synonyms

GTPL8213; BDBM50361564

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
IL-1 receptor-associated kinase 3 (IRAK3)	TTBPJOK	IRAK3_HUMAN	Inhibitor	[1]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[1]
Serine/threonine-protein kinase ULK1 (ULK1)	TT4D7MJ	ULK1_HUMAN	Inhibitor	[1]
Sugen kinase 110 (SBK3)	TTYNM3X	SBK3_HUMAN	Inhibitor	[1]
Tie-1 tyrosine kinase receptor (TIE1)	TTT4236	TIE1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Proto-oncogene c-Met (MET)	DTT	MET	6.737	6.293	7.744	6.879

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proto-oncogene c-Met (MET)	DTT	MET	1.08E-03	-0.24	-0.4

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.